Cargando…
Intraoperative electron radiotherapy in early invasive ductal breast cancer: 6-year median follow-up results of a prospective monocentric registry
BACKGROUND: Intraoperative electron radiotherapy (IOERT) can be used to treat early breast cancer during the conservative surgery thus enabling shorter overall treatment times and reduced irradiation of organs at risk. We report on our first 996 patients enrolled prospectively in a registry trial. M...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685863/ https://www.ncbi.nlm.nih.gov/pubmed/36419161 http://dx.doi.org/10.1186/s13058-022-01582-4 |
_version_ | 1784835613549133824 |
---|---|
author | Philippson, Catherine Larsen, Samuel Simon, Stéphane Vandekerkhove, Christophe De Caluwe, Alex Van Gestel, Dirk Chintinne, Marie Veys, Isabelle De Neubourg, Filip Noterman, Danièle Roman, Mirela Nogaret, Jean-Marie Desmet, Antoine |
author_facet | Philippson, Catherine Larsen, Samuel Simon, Stéphane Vandekerkhove, Christophe De Caluwe, Alex Van Gestel, Dirk Chintinne, Marie Veys, Isabelle De Neubourg, Filip Noterman, Danièle Roman, Mirela Nogaret, Jean-Marie Desmet, Antoine |
author_sort | Philippson, Catherine |
collection | PubMed |
description | BACKGROUND: Intraoperative electron radiotherapy (IOERT) can be used to treat early breast cancer during the conservative surgery thus enabling shorter overall treatment times and reduced irradiation of organs at risk. We report on our first 996 patients enrolled prospectively in a registry trial. METHODS: At Jules Bordet Institute, from February 2010 onwards, patients underwent partial IOERT of the breast. Women with unifocal invasive ductal carcinoma, aged 40 years or older, with a clinical tumour size ≤ 20 mm and tumour-free sentinel lymph node (on frozen section and immunohistochemical analysis). A 21 Gy dose was prescribed on the 90% isodose line in the tumour bed with the energy of 6 to 12 MeV (Mobetron®-IntraOp Medical). RESULTS: Thirty-seven ipsilateral tumour relapses occurred. Sixteen of those were in the same breast quadrant. Sixty patients died, and among those, 12 deaths were due to breast cancer. With 71.9 months of median follow-up, the 5-year Kaplan–Meier estimate of local recurrence was 2.7%. CONCLUSIONS: The rate of breast cancer local recurrence after IOERT is low and comparable to published results for IORT and APBI. IOERT is highly operator-dependent, and appropriate applicator sizing according to tumour size is critical. When used in a selected patient population, IOERT achieves a good balance between tumour control and late radiotherapy-mediated toxicity morbidity and mortality thanks to insignificant irradiation of organs at risk. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13058-022-01582-4. |
format | Online Article Text |
id | pubmed-9685863 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-96858632022-11-25 Intraoperative electron radiotherapy in early invasive ductal breast cancer: 6-year median follow-up results of a prospective monocentric registry Philippson, Catherine Larsen, Samuel Simon, Stéphane Vandekerkhove, Christophe De Caluwe, Alex Van Gestel, Dirk Chintinne, Marie Veys, Isabelle De Neubourg, Filip Noterman, Danièle Roman, Mirela Nogaret, Jean-Marie Desmet, Antoine Breast Cancer Res Research BACKGROUND: Intraoperative electron radiotherapy (IOERT) can be used to treat early breast cancer during the conservative surgery thus enabling shorter overall treatment times and reduced irradiation of organs at risk. We report on our first 996 patients enrolled prospectively in a registry trial. METHODS: At Jules Bordet Institute, from February 2010 onwards, patients underwent partial IOERT of the breast. Women with unifocal invasive ductal carcinoma, aged 40 years or older, with a clinical tumour size ≤ 20 mm and tumour-free sentinel lymph node (on frozen section and immunohistochemical analysis). A 21 Gy dose was prescribed on the 90% isodose line in the tumour bed with the energy of 6 to 12 MeV (Mobetron®-IntraOp Medical). RESULTS: Thirty-seven ipsilateral tumour relapses occurred. Sixteen of those were in the same breast quadrant. Sixty patients died, and among those, 12 deaths were due to breast cancer. With 71.9 months of median follow-up, the 5-year Kaplan–Meier estimate of local recurrence was 2.7%. CONCLUSIONS: The rate of breast cancer local recurrence after IOERT is low and comparable to published results for IORT and APBI. IOERT is highly operator-dependent, and appropriate applicator sizing according to tumour size is critical. When used in a selected patient population, IOERT achieves a good balance between tumour control and late radiotherapy-mediated toxicity morbidity and mortality thanks to insignificant irradiation of organs at risk. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13058-022-01582-4. BioMed Central 2022-11-23 2022 /pmc/articles/PMC9685863/ /pubmed/36419161 http://dx.doi.org/10.1186/s13058-022-01582-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Philippson, Catherine Larsen, Samuel Simon, Stéphane Vandekerkhove, Christophe De Caluwe, Alex Van Gestel, Dirk Chintinne, Marie Veys, Isabelle De Neubourg, Filip Noterman, Danièle Roman, Mirela Nogaret, Jean-Marie Desmet, Antoine Intraoperative electron radiotherapy in early invasive ductal breast cancer: 6-year median follow-up results of a prospective monocentric registry |
title | Intraoperative electron radiotherapy in early invasive ductal breast cancer: 6-year median follow-up results of a prospective monocentric registry |
title_full | Intraoperative electron radiotherapy in early invasive ductal breast cancer: 6-year median follow-up results of a prospective monocentric registry |
title_fullStr | Intraoperative electron radiotherapy in early invasive ductal breast cancer: 6-year median follow-up results of a prospective monocentric registry |
title_full_unstemmed | Intraoperative electron radiotherapy in early invasive ductal breast cancer: 6-year median follow-up results of a prospective monocentric registry |
title_short | Intraoperative electron radiotherapy in early invasive ductal breast cancer: 6-year median follow-up results of a prospective monocentric registry |
title_sort | intraoperative electron radiotherapy in early invasive ductal breast cancer: 6-year median follow-up results of a prospective monocentric registry |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685863/ https://www.ncbi.nlm.nih.gov/pubmed/36419161 http://dx.doi.org/10.1186/s13058-022-01582-4 |
work_keys_str_mv | AT philippsoncatherine intraoperativeelectronradiotherapyinearlyinvasiveductalbreastcancer6yearmedianfollowupresultsofaprospectivemonocentricregistry AT larsensamuel intraoperativeelectronradiotherapyinearlyinvasiveductalbreastcancer6yearmedianfollowupresultsofaprospectivemonocentricregistry AT simonstephane intraoperativeelectronradiotherapyinearlyinvasiveductalbreastcancer6yearmedianfollowupresultsofaprospectivemonocentricregistry AT vandekerkhovechristophe intraoperativeelectronradiotherapyinearlyinvasiveductalbreastcancer6yearmedianfollowupresultsofaprospectivemonocentricregistry AT decaluwealex intraoperativeelectronradiotherapyinearlyinvasiveductalbreastcancer6yearmedianfollowupresultsofaprospectivemonocentricregistry AT vangesteldirk intraoperativeelectronradiotherapyinearlyinvasiveductalbreastcancer6yearmedianfollowupresultsofaprospectivemonocentricregistry AT chintinnemarie intraoperativeelectronradiotherapyinearlyinvasiveductalbreastcancer6yearmedianfollowupresultsofaprospectivemonocentricregistry AT veysisabelle intraoperativeelectronradiotherapyinearlyinvasiveductalbreastcancer6yearmedianfollowupresultsofaprospectivemonocentricregistry AT deneubourgfilip intraoperativeelectronradiotherapyinearlyinvasiveductalbreastcancer6yearmedianfollowupresultsofaprospectivemonocentricregistry AT notermandaniele intraoperativeelectronradiotherapyinearlyinvasiveductalbreastcancer6yearmedianfollowupresultsofaprospectivemonocentricregistry AT romanmirela intraoperativeelectronradiotherapyinearlyinvasiveductalbreastcancer6yearmedianfollowupresultsofaprospectivemonocentricregistry AT nogaretjeanmarie intraoperativeelectronradiotherapyinearlyinvasiveductalbreastcancer6yearmedianfollowupresultsofaprospectivemonocentricregistry AT desmetantoine intraoperativeelectronradiotherapyinearlyinvasiveductalbreastcancer6yearmedianfollowupresultsofaprospectivemonocentricregistry |